The Brief Introduction of Wanbang BiopharmaceuticalsWanbang Biopharmaceuticals (brief in "Wanbang Biopharma") is the core member of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (brief in "Fosun Pharma", stock code: 600196-SH, 02196-HK). Wanbang Biopharma was established in 1981 with the former name of Xuzhou Biochemical Pharmaceutical Factory, reformed to Xuzhou Wanbang Biochemistry Pharmaceuticals Ltd in 1998, named as Jiangsu Wanbang Biopharmaceuticals Co., Ltd in 2001, joined in Fosun Pharma in 2004, and upgraded to Wanbang Biopharma Group in 2017.Wanbang Biopharma has domestic first-class prokaryotic and eukaryotic gene cell engineering pharmaceutical research and production site. Through equity participation, Wanbang established a small molecule innovative drug research and development laboratory in San Francisc, United States, so it also is in the leading position of high difficulty generics in the industry. Wanbang invests about 10% of the sales revenue for new product research and development. Wanbang's R&D team has over 200 full-time staff, among which over 50% are highly qualified personnel such as master's degree and doctoral degree. Each year, averagely, they apply for more than twenty national patents and several new products are launched into market.Wanbang Biopharma holding manages 17 subsidiaries (please find the list in the annex) and has established 10 manufacturing sites throughout China. It has the qualifications of pharmaceutical products production, wholesale, chain drugstores, internet sales and other related business qualification. Wanbang Biopharma recently invested nearly 600 million RMB to design and built a cGMP standard biological product workshop and FPF joint workshop according to European and American pharmaceutical management concepts, whose key production and analysis equipment are top leading of the world.